Kardigan Prices Upsized Initial Public Offering at $16 Per Share

What's Happening? Kardigan, a clinical-stage precision therapeutics company, has announced the pricing of its initial public offering (IPO) at $16 per share. The offering includes 25,000,000 shares of common stock, with expected gross proceeds of $400 million. The company's stock is set to begin tra

Money & Investing

SEE ALL

Trendline

bioAffinity Technologies Prices $3.2 Million Offering for Lung Cancer Detection Test

Trendline

Gina Rinehart Invests $1.4 Billion in SpaceX, Expanding Her Portfolio

Trendline

AI Revolutionizes Traditional 60/40 Investment Portfolio Strategy

What is the story about?

What's Happening?

Kardigan, a clinical-stage precision therapeutics company, has announced the pricing of its initial public offering (IPO) at $16 per share. The offering includes 25,000,000 shares of common stock, with expected gross proceeds of $400 million. The company's

stock is set to begin trading on the Nasdaq Global Market under the ticker symbol 'KARD'. The IPO is managed by underwriters J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and TD Securities (USA) LLC.

Why It's Important?

Kardigan's IPO represents a significant milestone for the company as it seeks to raise capital to advance its development of precision therapeutics targeting cardiovascular diseases. The successful pricing and anticipated trading on Nasdaq could enhance Kardigan's visibility and credibility in the biotech industry, attracting more investors and facilitating future growth. The funds raised will likely support the company's research and development efforts, potentially leading to breakthroughs in cardiovascular treatments where no approved therapies currently exist.